Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 6/20 | 0.58 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.48 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.48 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.48 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.48 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.48 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.48 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 0.48 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.48 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 13/20 | 0.53 |
| ▸ | RAF1 | P04049 | 9/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | ROS1 | P08922 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618015 | 0.99 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL12355381 | 0.88 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL940461 | 0.88 | KDR (0.62) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL6014811 | 0.87 | KDR (0.63) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL619670 | 0.85 | KDR (0.58) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL12355368 | 0.85 | KDR (0.58) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL400592 | 0.85 | KDR (0.58) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL29396481 | 0.85 | KDR (0.58) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL4328009 | 0.84 | RAF1 (0.49) | KDRBRAFRAF1EPHX2 | |
| SCHEMBL16651380 | 0.84 | KDR (0.67) | KDRBRAFRAF1EPHX2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8124630-B2 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2298311-A1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | Bayer Healthcare Llc (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7897623-B2 | FDA Orange book listed patent for sorafenib tosylate; tablets | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1690853-B1 | Use of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20020165394-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER CORPORATION | 2002-11-07 | — | — | US | disclosed |
| US-20020137774-A1 | Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-09-26 | — | — | US | disclosed |
| WO-2002062763-A2 | INHIBITION OF RAF KINASE USING QUINOLYL ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | disclosed |
| CN-1341098-A | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER AG (US) | 2002-03-20 | — | — | CN | disclosed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 611/4885CSF1R 2611/4885JAK2 600/4885 |
| US-20020165394-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BRAF, RAF1, ARAF | KDR 1324/4885CSF1R 2100/4885JAK2 425/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | KDR 624/4885CSF1R 2477/4885JAK2 417/4885 |
| US-20020137774-A1 | Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, NRAS | KDR 609/4885CSF1R 2334/4885JAK2 523/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 567/4885CSF1R 2436/4885JAK2 516/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 567/4885CSF1R 2436/4885JAK2 516/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDR 456/4885CSF1R 1561/4885JAK2 389/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | KDR 487/4885CSF1R 1823/4885JAK2 574/4885 |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 567/4885CSF1R 2436/4885JAK2 516/4885 |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, NRAS, RAF1 | KDR 558/4885CSF1R 2795/4885JAK2 531/4885 |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDR 567/4885CSF1R 2436/4885JAK2 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.